First in Human Study of AZD9592 in Solid Tumors
Running, not enrolling · Phase 1
Conditions studied: Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
In brief
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.
Key facts
- Study ID
- NCT05647122
- Run by
- AstraZeneca
- People needed
- 167
- Starts
- 2022-12-21
- Expected to finish
- 2028-08-03
- Last updated by the study team
- 2026-06-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Toronto, Ontario, Canada
- Research Site — Beijing, China
- Research Site — Chongqing, China
- Research Site — Guangzhou, China
- Research Site — Wuhan, China
- Research Site — Marseille, France
- Research Site — Rennes, France
- Research Site — Villejuif, France
- Research Site — Milan, Italy
- Research Site — Orbassano, Italy
- Research Site — Rozzano, Italy
- Research Site — Verona, Italy
- Research Site — Chūōku, Japan
- Research Site — Kashiwa, Japan
- Research Site — Kōtoku, Japan
- Research Site — Kuala Lumpur, Malaysia
- Research Site — Kuching, Malaysia
- Research Site — Seoul, South Korea
- Research Site — Seoul, South Korea
- Research Site — Seoul, South Korea
- Research Site — Seoul, South Korea
- Research Site — Barcelona, Spain
- Research Site — Madrid, Spain
- Research Site — Seville, Spain
- Research Site — Taichung, Taiwan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.